SGRY Stock Forecast 2025-2026
Distance to SGRY Price Targets
SGRY Price Momentum
10 Quality Stocks Worth Considering Now
Researching Surgery Partners (SGRY) after the drop? Our ex-Goldman Sachs analyst reveals if it made our list of 10 oversold quality stocks with strong growth potential.
Get our FREE market selloff report + exclusive analysis on SGRY and similar high-potential opportunities.
Latest SGRY Stock Price Targets & Analyst Predictions
Based on our analysis of 19 Wall Street analysts, SGRY has a bullish consensus with a median price target of $33.00 (ranging from $24.00 to $36.00). The overall analyst rating is Strong Buy (8.8/10). Currently trading at $24.02, the median forecast implies a 37.4% upside. This outlook is supported by 9 Buy, 3 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Jason Cassorla at Citigroup, projecting a 49.9% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
SGRY Analyst Ratings
SGRY Price Target Range
Latest SGRY Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for SGRY.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Mar 25, 2025 | RBC Capital | Ben Hendrix | Outperform | Reiterates | $35.00 |
| Mar 11, 2025 | Macquarie | Tao Qiu | Outperform | Maintains | $33.00 |
| Dec 3, 2024 | JP Morgan | Lisa Gill | Neutral | Maintains | $28.00 |
| Nov 20, 2024 | RBC Capital | Ben Hendrix | Outperform | Maintains | $35.00 |
| Nov 19, 2024 | Macquarie | Tao Qiu | Outperform | Maintains | $34.00 |
| Nov 13, 2024 | Macquarie | Tao Qiu | Outperform | Maintains | $34.00 |
| Nov 4, 2024 | Macquarie | Tao Qiu | Outperform | Maintains | $35.00 |
| Oct 14, 2024 | UBS | A.J. Rice | Buy | Initiates | $38.00 |
| Oct 11, 2024 | Keybanc | Matthew Gillmor | Sector Weight | Initiates | $0.00 |
| Oct 4, 2024 | Cantor Fitzgerald | Sarah James | Overweight | Reiterates | $43.00 |
| Aug 26, 2024 | Benchmark | Bill Sutherland | Buy | Reiterates | $50.00 |
| Aug 20, 2024 | Cantor Fitzgerald | Sarah James | Overweight | Reiterates | $43.00 |
| Aug 19, 2024 | Cantor Fitzgerald | Sarah James | Overweight | Reiterates | $43.00 |
| Aug 7, 2024 | RBC Capital | Ben Hendrix | Outperform | Reiterates | $49.00 |
| Aug 7, 2024 | Citigroup | Jason Cassorla | Buy | Maintains | $36.00 |
| Aug 7, 2024 | Benchmark | Bill Sutherland | Buy | Reiterates | $50.00 |
| Jul 10, 2024 | Cantor Fitzgerald | Sarah James | Overweight | Reiterates | $43.00 |
| Jul 9, 2024 | Cantor Fitzgerald | Sarah James | Overweight | Reiterates | $43.00 |
| Jul 2, 2024 | Cantor Fitzgerald | Sarah James | Overweight | Reiterates | $43.00 |
| Jun 28, 2024 | Macquarie | Tao Qiu | Outperform | Initiates | $31.00 |
Surgery Partners Inc. (SGRY) Competitors
The following stocks are similar to Surgery Partners based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Surgery Partners Inc. (SGRY) Financial Data
Surgery Partners Inc. has a market capitalization of $3.07B with a P/E ratio of 2,956.0x. The company generates $3.11B in trailing twelve-month revenue with a -5.4% profit margin.
Revenue growth is +17.5% quarter-over-quarter, while maintaining an operating margin of +20.0% and return on equity of +0.4%.
Valuation Metrics
Growth & Margins
Financial Health
Get All 10 Quality Stocks For This Market Selloff
Still researching investments after the market drop? Our ex-Goldman Sachs analyst has already identified the 10 highest-quality oversold stocks with strong fundamentals and upside potential.
Why spend hours researching when we've already done the work? Get instant access to our complete market selloff analysis.
Surgery Partners Inc. (SGRY) Business Model
About Surgery Partners Inc.
Provides outpatient surgical healthcare services.
The company operates ambulatory surgical centers (ASCs), hospitals, and physician practices, generating revenue by performing outpatient surgical procedures. By focusing on high-quality care and advanced medical technologies, Surgery Partners Inc. collaborates with healthcare practitioners to enhance patient outcomes and streamline surgical processes.
Surgery Partners Inc. plays a crucial role in the growing outpatient care market, which is more cost-effective than traditional hospitals. With a broad range of surgical disciplines and a nationwide presence, the company is well-positioned to adapt to evolving healthcare trends and patient needs.
Company Information
Sector
Healthcare
Industry
Medical Care Facilities
Employees
15,000
CEO
Mr. J. Eric Evans
Country
United States
IPO Year
2015
Website
www.surgerypartners.comSurgery Partners Inc. (SGRY) Latest News & Analysis
Surgery Partners, Inc. (NASDAQ:SGRY) will hold its Q4 2024 Earnings Conference Call on March 3, 2025, at 8:30 AM ET, featuring key executives and notable analysts from major firms.
Surgery Partners' earnings call will provide insights on financial performance and strategic direction, impacting stock valuation and investor sentiment. Key analysts will assess growth potential and risks.
Surgery Partners (SGRY) reported quarterly earnings of $0.44 per share, exceeding the Zacks Consensus Estimate of $0.38, matching the earnings from the same quarter last year.
Surgery Partners' earnings beat expectations, indicating strong performance and operational stability, which may boost investor confidence and affect stock price positively.
REITs have increased in value, but income-oriented investors can still find opportunities. Two specific REITs are recommended for purchase.
Surging REIT values indicate strong market interest, yet continued opportunities suggest potential for income generation, attracting yield-seeking investors.
Surgery Partners, Inc. Announces Fourth Quarter 2024 Earnings Release Date and Conference Call Details
1 month agoSurgery Partners, Inc. (NASDAQ: SGRY) will announce its Q4 2024 results on March 3, 2025, before market open, followed by a conference call at 8:30 a.m. ET.
Surgery Partners' upcoming earnings release and conference call may significantly impact stock prices, influencing investor sentiment and market expectations for the company's performance.
In 2024, Japan's private equity investment surged nearly 41%, significantly exceeding the global average increase of 25% in deal value, as reported by S&P Global Market Intelligence.
Japan's 41% surge in private equity investment signals strong market confidence and growth potential, attracting attention from investors seeking lucrative opportunities.
Bain Capital Private Equity plans to acquire the remaining shares of Surgery Partners for $25.75 each, according to a recent filing.
Bain Capital's acquisition proposal for Surgery Partners at $25.75 per share indicates potential growth and consolidation in the surgical facility sector, impacting stock valuation and investor sentiment.
Frequently Asked Questions About SGRY Stock
What is Surgery Partners Inc.'s (SGRY) stock forecast for 2025?
Based on our analysis of 19 Wall Street analysts, Surgery Partners Inc. (SGRY) has a median price target of $33.00. The highest price target is $36.00 and the lowest is $24.00.
Is SGRY stock a good investment in 2025?
According to current analyst ratings, SGRY has 9 Buy ratings, 3 Hold ratings, and 0 Sell ratings. The stock is currently trading at $24.02. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for SGRY stock?
Wall Street analysts predict SGRY stock could reach $33.00 in the next 12 months. This represents a 37.4% increase from the current price of $24.02. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Surgery Partners Inc.'s business model?
The company operates ambulatory surgical centers (ASCs), hospitals, and physician practices, generating revenue by performing outpatient surgical procedures. By focusing on high-quality care and advanced medical technologies, Surgery Partners Inc. collaborates with healthcare practitioners to enhance patient outcomes and streamline surgical processes.
What is the highest forecasted price for SGRY Surgery Partners Inc.?
The highest price target for SGRY is $36.00 from Jason Cassorla at Citigroup, which represents a 49.9% increase from the current price of $24.02.
What is the lowest forecasted price for SGRY Surgery Partners Inc.?
The lowest price target for SGRY is $24.00 from at , which represents a -0.1% decrease from the current price of $24.02.
What is the overall SGRY consensus from analysts for Surgery Partners Inc.?
The overall analyst consensus for SGRY is bullish. Out of 19 Wall Street analysts, 9 rate it as Buy, 3 as Hold, and 0 as Sell, with a median price target of $33.00.
How accurate are SGRY stock price projections?
Stock price projections, including those for Surgery Partners Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
